eXp World (EXPI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue increased 5% year-over-year to $1.30 billion, driven by higher agent productivity and home sales prices, despite a 1% decline in agent count and a challenging U.S. real estate market.
Adjusted EBITDA rose 22% year-over-year to $32.8 million, reflecting improved cost efficiencies, revenue growth, and a profit improvement plan.
Net income from continuing operations was $11.8 million, up 4% year-over-year; diluted EPS from continuing operations was $0.08.
Returned $56 million to shareholders through $48.2 million in share repurchases and $7.5 million in dividends.
Agent Net Promoter Score improved to 76, reflecting enhanced agent support and technology investments.
Financial highlights
Q2 2024 revenue: $1.30 billion, up 5% year-over-year; sales volume: $51.9 billion, up 7%.
Adjusted EBITDA: $32.8 million, up 22%; operating income: $18.5 million, up 44% year-over-year.
Net income from continuing operations: $11.8 million; total net income including discontinued operations: $12.4 million.
Cash and cash equivalents at June 30, 2024: $108.4 million; adjusted operating cash flow: $60.4 million.
Cost per transaction decreased 8% year-over-year.
Outlook and guidance
Management expects continued market challenges due to high mortgage rates and regulatory changes but is focused on agent productivity, technology investment, and international growth.
Gross margin for the second half expected to follow typical seasonal patterns and be similar to 2023.
SG&A expected to rise mid-single digits in H2 due to salary adjustments, event timing, and legal costs.
No material changes to critical accounting policies or estimates are anticipated for the remainder of 2024.
Latest events from eXp World
- Shareholders are asked to approve redomestication to Texas, aligning governance with business needs.EXPI
Proxy filing24 Apr 2026 - Shareholders will vote on redomestication to Texas, with key risks and benefits highlighted.EXPI
Proxy filing23 Apr 2026 - Shareholders will vote on redomestication to Texas, with new litigation thresholds and outlined risks.EXPI
Proxy filing23 Apr 2026 - Shareholders are voting on a Texas redomestication, with enhanced governance and voting safeguards.EXPI
Proxy filing23 Apr 2026 - Stockholders will vote on redomestication to Texas, aiming for financial and governance benefits.EXPI
Proxy filing22 Apr 2026 - Proxy solicitor engaged for 2026 Annual Meeting to support redomestication vote.EXPI
Proxy filing20 Apr 2026 - Shareholders to vote on Texas redomestication, governance, and compensation changes.EXPI
Proxy Filing9 Mar 2026 - Board recommends approval of director elections, auditor, executive pay, and Texas redomestication.EXPI
Proxy Filing25 Feb 2026 - 2025 revenue rose 4% to $4.8B, with 67% international growth and strong agent productivity.EXPI
Q4 202524 Feb 2026